# OnCo record akt1-e17k (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/akt1-e17k/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "akt1-e17k" ;
  schema:name "AKT1 E17K mutation"@en ;
  schema:alternateName "AKT1 E17K"@en, "AKT1 mutation"@en, "E17K"@en, "AKT1-mutant"@en ;
  schema:description "AKT1 E17K is a single hotspot mutation, in about 3 to 5 percent of hormone-receptor-positive breast cancers, that switches on the AKT kinase directly. It is one of the three alterations that qualify a patient for capivasertib."@en ;
  schema:url <https://onco.cc/biomarkers/akt1-e17k/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d698c106-2322-401e-b738-cbd83c843ecf> ;
  onco:tag "biomarker", "pi3k" ;
  onco:related <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/>, <https://onco.cc/biomarkers/pten-alteration/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/endometrial/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/foundationone-cdx/> ;
  onco:terms <https://onco.cc/terms/hyperglycaemia/> .